Oculis (NASDAQ:OCS) Stock Price Expected to Rise, Chardan Capital Analyst Says

Oculis (NASDAQ:OCS - Free Report) had its price target lifted by Chardan Capital from $28.00 to $33.00 in a research report sent to investors on Friday,Benzinga reports. They currently have a buy rating on the stock.

A number of other equities research analysts also recently commented on the company. Robert W. Baird boosted their target price on Oculis from $37.00 to $41.00 and gave the stock an "outperform" rating in a research report on Thursday, March 13th. HC Wainwright boosted their target price on shares of Oculis from $29.00 to $32.00 and gave the stock a "buy" rating in a report on Thursday, April 17th.

Oculis Stock Performance

Shares of Oculis stock traded down $0.46 during trading hours on Friday, reaching $17.30. The company had a trading volume of 9,984 shares, compared to its average volume of 43,457. Oculis has a one year low of $10.79 and a one year high of $23.08. The business has a fifty day simple moving average of $17.99 and a 200 day simple moving average of $18.40. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.02 and a quick ratio of 4.02. The firm has a market cap of $755.35 million, a PE ratio of -8.96 and a beta of 0.27.

Oculis (NASDAQ:OCS - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($0.77) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.26). Oculis had a negative return on equity of 71.31% and a negative net margin of 8,043.28%. The firm had revenue of $0.32 million during the quarter, compared to analysts' expectations of $0.22 million. On average, analysts anticipate that Oculis will post -2.09 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. abrdn plc increased its position in shares of Oculis by 23.0% in the 4th quarter. abrdn plc now owns 1,009,424 shares of the company's stock valued at $17,150,000 after purchasing an additional 188,871 shares during the last quarter. Geode Capital Management LLC increased its position in Oculis by 12.0% during the 4th quarter. Geode Capital Management LLC now owns 16,744 shares of the company's stock worth $284,000 after purchasing an additional 1,800 shares during the period. XTX Topco Ltd purchased a new stake in shares of Oculis during the 4th quarter worth $225,000. Bellevue Group AG purchased a new position in Oculis in the fourth quarter valued at about $170,000. Finally, Bank of America Corp DE grew its holdings in Oculis by 58.2% in the fourth quarter. Bank of America Corp DE now owns 28,980 shares of the company's stock valued at $493,000 after purchasing an additional 10,667 shares during the last quarter. Institutional investors and hedge funds own 22.30% of the company's stock.

Oculis Company Profile

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.